Adaptimmune says mid-stage trial for afami-cel in soft tissue cancer will meet main goal
12 November 2021 - 1:51AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024